CLLS Stock Summary and Trading Ideas (Cellectis S.A. - American Depositary Shares | NASDAQ:CLLS)

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Cellectis S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol CLLS.

As of January 16, 2026, CLLS stock price declined to $4.07 with 70,727 million shares trading.

CLLS has a beta of 0.94, meaning it tends to be less sensitive to market movements. CLLS has a correlation of 0.05 to the broad based SPY ETF.

CLLS has a market cap of $408.18 million. This is considered a Small Cap stock.

Last quarter Cellectis S.A. - American Depositary Shares reported $37 million in Revenue and $.02 earnings per share. This beat revenue expectation by $29 million and exceeded earnings estimates by $.12.

In the last 3 years, CLLS traded as high as $5.48 and as low as $.96.

The top ETF exchange traded funds that CLLS belongs to (by Net Assets): IBB.

CLLS has outperformed the market in the last year with a return of +148.2%, while the SPY ETF gained +17.9%. However, in the most recent history, CLLS shares have underperformed the stock market with its stock returning -1.0% in the last 3 month period and -15.9% for the last 2 week period, while SPY has returned +4.3% and +1.4%, respectively.

CLLS support price is $3.92 and resistance is $4.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLLS shares will trade within this expected range on the day.